Tags

Type your tag names separated by a space and hit enter

A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
Int J Hematol. 1999 Jan; 69(1):27-35.IJ

Abstract

We established a simple method of T cell depletion using anti-CD6 monoclonal antibody-conjugated immunomagnetic beads. Preliminary experiments using this method demonstrated that CD3+ T cells could be partially depleted without depleting CD56+ NK cells. A phase I-II clinical study was performed to assess the safety and efficacy of this partial T cell depletion method for the prevention of acute graft-vs.-host disease (GVHD) in 10 leukemia patients at high risk for GVHD (defined as 1) unrelated transplant from MLC-positive or HLA-DRB1 mismatched donor or 2) related transplant from serologically HLA-A, -B, or -DR one-locus mismatched donor). Cyclosporine (CSP) and methotrexate (MTX) were used for additional prophylaxis against GVHD in all cases. Sustained engraftment occurred in 9 of the 10 patients. Although acute GVHD developed in 6 of the 9 evaluable patients, none developed more than grade III severe acute GVHD. Five patients were alive in remission at a median follow-up of 32 months after bone marrow transplantation, and no relapse of leukemia was observed. We conclude from this pilot study that selective T cell depletion with anti-CD6 monoclonal antibody coupled with CSP and MTX posttransplant immunosuppressive therapy is safe. Further analysis of the phase II-III study is needed to confirm the effectiveness of this protocol.

Authors+Show Affiliations

Department of Hematology, Meitetsu Hospital, Nagoya, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10641440

Citation

Sao, H, et al. "A New Marrow T Cell Depletion Method Using anti-CD6 Monoclonal Antibody-conjugated Magnetic Beads and Its Clinical Application for Prevention of Acute Graft-vs.-host Disease in Allogeneic Bone Marrow Transplantation: Results of a Phase I-II Trial." International Journal of Hematology, vol. 69, no. 1, 1999, pp. 27-35.
Sao H, Kitaori K, Kasai M, et al. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial. Int J Hematol. 1999;69(1):27-35.
Sao, H., Kitaori, K., Kasai, M., Shimokawa, T., Kato, C., Yamanishi, H., Ueda, R., & Morishima, Y. (1999). A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial. International Journal of Hematology, 69(1), 27-35.
Sao H, et al. A New Marrow T Cell Depletion Method Using anti-CD6 Monoclonal Antibody-conjugated Magnetic Beads and Its Clinical Application for Prevention of Acute Graft-vs.-host Disease in Allogeneic Bone Marrow Transplantation: Results of a Phase I-II Trial. Int J Hematol. 1999;69(1):27-35. PubMed PMID: 10641440.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial. AU - Sao,H, AU - Kitaori,K, AU - Kasai,M, AU - Shimokawa,T, AU - Kato,C, AU - Yamanishi,H, AU - Ueda,R, AU - Morishima,Y, PY - 2000/1/21/pubmed PY - 2000/2/19/medline PY - 2000/1/21/entrez SP - 27 EP - 35 JF - International journal of hematology JO - Int J Hematol VL - 69 IS - 1 N2 - We established a simple method of T cell depletion using anti-CD6 monoclonal antibody-conjugated immunomagnetic beads. Preliminary experiments using this method demonstrated that CD3+ T cells could be partially depleted without depleting CD56+ NK cells. A phase I-II clinical study was performed to assess the safety and efficacy of this partial T cell depletion method for the prevention of acute graft-vs.-host disease (GVHD) in 10 leukemia patients at high risk for GVHD (defined as 1) unrelated transplant from MLC-positive or HLA-DRB1 mismatched donor or 2) related transplant from serologically HLA-A, -B, or -DR one-locus mismatched donor). Cyclosporine (CSP) and methotrexate (MTX) were used for additional prophylaxis against GVHD in all cases. Sustained engraftment occurred in 9 of the 10 patients. Although acute GVHD developed in 6 of the 9 evaluable patients, none developed more than grade III severe acute GVHD. Five patients were alive in remission at a median follow-up of 32 months after bone marrow transplantation, and no relapse of leukemia was observed. We conclude from this pilot study that selective T cell depletion with anti-CD6 monoclonal antibody coupled with CSP and MTX posttransplant immunosuppressive therapy is safe. Further analysis of the phase II-III study is needed to confirm the effectiveness of this protocol. SN - 0925-5710 UR - https://www.unboundmedicine.com/medline/citation/10641440/A_new_marrow_T_cell_depletion_method_using_anti_CD6_monoclonal_antibody_conjugated_magnetic_beads_and_its_clinical_application_for_prevention_of_acute_graft_vs__host_disease_in_allogeneic_bone_marrow_transplantation:_results_of_a_phase_I_II_trial_ L2 - http://www.diseaseinfosearch.org/result/7171 DB - PRIME DP - Unbound Medicine ER -